Single-Use Systems E&L: BPOG/PQRI Alignment That Holds Up



Single-Use Systems E&L: BPOG/PQRI Alignment That Holds Up

Published on 10/12/2025

Single-Use Systems E&L: BPOG/PQRI Alignment That Holds Up

In the evolving landscape of pharmaceuticals, extractables and leachables (E&L) testing has emerged as a critical component in the validation of single-use systems, filters, and packaging. With a focus on regulatory compliance under US FDA, EMA, MHRA, and PIC/S guidelines, this guide outlines a step-by-step process for achieving alignment with the PQRI guideline and ensuring that validations hold up against scrutiny. It encompasses essential principles such as Analytical Evaluation Threshold (AET), Dose-Based Threshold (DBT), and Container Closure Integrity (CCI) testing, integral for maintaining product integrity and patient safety.

Understanding Extractables and Leachables

The fundamental concepts of E&L involve understanding how materials in contact with drug products can influence product quality. Extractables are the compounds that leach from packaging or delivery systems under extreme conditions, while leachables are the substances detected under normal storage conditions. Regulatory guidelines emphasize rigorous testing to ensure that these compounds do not adversely affect drug efficacy or safety.

The increase in the use of single-use systems in biopharmaceutical manufacturing has necessitated comprehensive assessments of these materials. Under EU GMP Annex 1, manufacturers are required to validate the safety and biocompatibility of single-use solutions. Laboratories must establish appropriate methodologies to quantify E&L, keeping patient safety at the forefront.

Regulatory Framework for E&L Testing

Regulatory authorities including the FDA and EMA provide guidelines that emphasize the importance of a scientifically valid approach to E&L testing. The FDA has documented specific requirements for E&L in combination with its established frameworks for quality assurance. The PQRI guidelines offer a substantial resource for manufacturers, outlining a risk-based approach that can be applied to analyze materials used in biopharmaceutical production.

To ensure compliance, the following components are essential:

  • Comprehensive documentation: All E&L studies must be documented thoroughly, detailing methodology, results, and conclusions.
  • Risk assessment: Conducting an E&L risk assessment to evaluate potential risks associated with single-use systems.
  • Validation protocols: Implementing specific validation protocols that meet the requirements defined by regulatory bodies.

Step-by-Step Guide on E&L Testing for Single-Use Systems

Below is a structured process to guide pharmaceutical professionals through the essential steps in evaluating E&L from single-use systems, including filters and bags. This holistic approach encompasses pre-validation, validation, and post-validation phases.

Step 1: Material Characterization

The initial step in the validation process must consist of a thorough characterization of the materials to understand the chemical composition of the components involved. This involves collecting data on the materials used in bags, filters, and other containers.

  • Identify material types: Different polymers, additives, and stabilizers can contribute to potential E&L.
  • Vendor assessments: Evaluate vendors based on their compliance history and quality management practices.

Step 2: Define E&L Testing Protocols

Once materials are identified and characterized, the next step involves defining the testing protocols. This includes the creation of suitable extraction conditions:

  • Selection of extraction solvents: Employ solvents that mimic the final product’s conditions (e.g., water for injections).
  • Temperature and Time: Establish relevant extraction conditions based on thermal stability of the materials.

It’s advisable to reference the PQRI guideline to determine appropriate extraction methodologies suited to specific single-use systems.

Step 3: Analytical Evaluation Threshold (AET) and Dose-Based Threshold (DBT) Calculation

AET calculations play a crucial role in establishing acceptable limits for leachables. The AET refers to the threshold below which the risk of a toxicological response is negligible. In contrast, DBT involves calculating the maximum allowable drug product exposure based on the leachables detected during testing.

The steps for performing AET and DBT calculations are:

  • Collect toxicological data: Use existing toxicological data to assess the safety of compounds.
  • Establish safety margins: Define acceptable safety levels for critical materials.
  • Calculate thresholds: Utilize the provided toxicological data to calculate AET and DBT.

Step 4: Testing and Data Collection

After protocols are established, the next phase focuses on testing to generate E&L data. Analytical techniques such as mass spectrometry, GC-MS, and HPLC should be utilized based on the materials under analysis. Key focus areas include:

  • Detecting leachables: Conduct analyses on extracts from various conditions to detect leachables.
  • Documenting analytical results: Compile and interpret the results meticulously as per regulatory requirements.

Container Closure Integrity (CCI) Testing

Container Closure Integrity is a paramount aspect of ensuring the quality and safety of pharmaceutical products, particularly in the context of single-use systems. CCI testing serves to confirm that no environment factors can compromise the product’s integrity.

Under USP CCI guidelines, manufacturers are encouraged to conduct CCI testing using methods that simulate real-world conditions such as manufacturing and storage.

  • Integrity Test Selection: Choose the appropriate testing method based on the product and packaging system (e.g., vacuum decay test, dye ingress test).
  • Environmental Conditions: Consider environmental factors that may affect the system during the life cycle of the product.

Post-Validation Surveillance and Risk Management

After validation, a robust post-validation strategy must be in place to monitor and manage risks associated with packaging materials. Risk assessments related to E&L should be continuous, considering changes in material formulation, supplier changes, or regulatory updates.

Steps to implement ongoing risk management are:

  • Periodic reviews: Regularly review E&L data after product distribution.
  • Setup feedback loops: Create channels for feedback from clinical operations to ensure any E&L concerns are addressed promptly.
  • Update risk assessments: Adjust risk assessment protocols and thresholds following new findings or regulatory guidance.

Conclusion

In summary, ensuring alignment with BPOG, PQRI guidelines, and establishing thorough E&L testing protocols is vital for the safe use of single-use systems in pharmaceuticals. With increased regulatory scrutiny from organizations such as the FDA, EMA, and PIC/S, adopting a systematic approach to validate extractables and leachables is not optional but mandatory. By following this step-by-step guide, pharmaceutical professionals can lay the groundwork for a comprehensive validation process that meets regulatory expectations and protects patient safety.